What defines the quality of patient care in tinea pedis?

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 2, 2006, Pages 158-165

  Mistik, Selcuk ^a   Ferahbas, A ^a   Koc, A N ^a   Ayangil, D ^a   Ozturk, A ^b  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b Kayseri Training and Research Hospital   (Turkey)

Author keywords

Antifungal susceptibility; Azoles; Terbinafine; Tinea pedis

Indexed keywords

ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROXOLAMINE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; OXICONAZOLE; SULCONAZOLE; TERBINAFINE;

ANALYTICAL ERROR; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DERMATOPHYTE; DILUTION; FEMALE; FUNGUS CULTURE; HEALTH CARE QUALITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT ATTITUDE; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; TINEA PEDIS; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; TRICHOSPORON; ADOLESCENT; ADULT; AGED; CANDIDA; CHILD; DEUTEROMYCETES; DRUG EFFECT; HEALTH CARE DELIVERY; HYGIENE; INTRADERMAL DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; PATHOLOGY; TRICHOPHYTON; TURKEY (REPUBLIC);

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CHILD; DELIVERY OF HEALTH CARE; FEMALE; HUMANS; HYGIENE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MITOSPORIC FUNGI; QUESTIONNAIRES; TINEA PEDIS; TRICHOPHYTON; TRICHOSPORON; TURKEY;

EID: 33646258263     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01396.x     Document Type: Article

References (43)

1. Bell-Syer SE, Hart R, Crawford F et al. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev 2002: CD003584.
2. Patel A, Brookman SD, Bullen MU et al. Topical treatment of interdigital tinea pedis: Terbinafine compared with clotrimazole. Australas J Dermatol 1999; 40: 197-200.
3. Haneke E. Achilles foot screening project: Background, objectives and design. J Eur Acad Dermatol Venereol 1999; 12: S2-S5.
4. Williams HC. The epidemiology of onycomycosis in Britain. Br J Dermatol 1993; 129: 101-109.
5. Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy 2004; 2: 5.
6. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician 2002; 65: 2095-2102.
7. Roseeuw D. Achilles foot screening project: Preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol 1999; 12: S6-S9.
8. Rinaldi MG. Dermatophytosis: Epidemiological and microbiological update. J Am Acad Dermatol 2000; 43: S120 -S124.
9. Hainer BL. Dermatophyte infections. Am Fam Physician 2003; 67: 101-108.
10. Vander Straten MR, Hossain MA, Ghannoum MA. Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor. Infect Dis Clin North Am; 17: 87-112.
11. Braun Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology, 2nd edn. Springer-Verlag, Berlin and Heidelberg, 2000.
12. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 2004; 48: 153-160.
13. Fernandez-Torres B, Carrillo AJ, Martin E et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 2001; 45: 2524-2528.
14. Ghannoum MA, Hajjeh RA, Scher R. A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-648.
15. Kane J, Summerbell RC. Trichophyton, Microsporum, Epidermophyton, and agents of superficial mycoses. In: Murray PR, Baron EJ, Pfaller MA, eds. Manual of Clinical Microbiology, 7th edn. ASM Press, Washington DC, 1999: 1275-1294.
16. Larone DH. Medically Important Fungi: A Guide to Identification, 2nd edn. ASM Press, Washington DC, 1993.
17. Glenn DR. Laboratory methods in basic mycology. In: Baron EJ, Peterson LR, Finegold SM, eds. Bailey and Scott's Diagnostic Microbiology, 9th edn. Mosby Year Book, St Louis, 1994: 689-775.
18. Espinel-Ingroff A. Commercial yeast identification systems. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook, Vol. 1. ASM Press, Washington DC, 1992, 6.10-6.11.
19. Mitchell TG. Opportunistic mycoses. In: Joklik WK, Willett HP, Amos DB, eds. Zinsser Microbiology, 20th edn. Appleton & Lange, Norwalk, 1992, 1135-1157.
20. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard. NCCLS document M27-A, National Committee for Clinical Laboratory Standards, Wayne PA 1997.
21. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; proposed standard. NCCLS document M38-P, National Committee for Clinical Laboratory Standards, Wayne PA 1998.
22. Espinel-Ingroff A, Barlett M, Bowden R et al. Multicenter evaluation of proposed standardised procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35: 139-143.
23. McGinnis MR, Rinaldi MG. Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biologic fluids. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Williams & Wilkins, Baltimore, 1996: 176-211.
24. Lyman CA, Walsh TJ. Systemically administered antifungal agents. Drugs 1992; 44: 9-35.
25. Milan EP, Burattini MN, Kallas EG et al. Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. Diagn Microbiol Infect Dis 1998; 32: 211-216.
26. Korting HC, Ollert M, Abeck D et al. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206-1208.
27. Richardson MD, Warnock DW. Dermatophytosis. In: Fungal Infection: Diagnosis and Treatment. Blackwell Scientific Publications, Oxford, England, 1993: 44-60.
28. Kamihama T, Kimura T, Hosokawa JI et al. Tinea pedis outbreak in swimming pools in Japan. Public Health 1997; 111: 249-253.
29. Stanford B. Athlete's foot. Physician Sports Med 1994; 22: 79-80.
30. Urabe H, Matsumoto T, Honbo S. Textbook of Medical Mycology. Kanehara, Tokyo, 1993: 59-61 (in Japanese).
31. Rand S. Overview: The treatment of dermatophytosis. J Am Acad Dermatol 2000; 43: S104-S112.
32. De Keyser P, De Backer M, Massart DL et al. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): A double-blind, multicentre study. Br J Dermatol 1994; 130: 22-25.
33. Hay RJ, McGregor JM, Wuite J et al. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatol 1995; 132: 604-608.
34. Tausch I, Decroix J, Gwiezdzinski Z et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol 1998; 37: 140-142.
35. Vermeer BJ, Staats CC, van Houwelingen JC. Terbinafine versus miconazole in patients with tinea pedis. Ned Tijdschr Geneeskd 1996; 140: 1605-1608.
36. Karaca N, Koc AN. In vitro susceptibility testing of dermatophytes: comparison of disk diffusion and reference broth dilution methods. Diagn Microbiol Infect Dis 2004; 48: 259-264.
37. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003; 149: 296-305.
38. Jessup CJ, Warner J, Isham N et al. Antifungal susceptibility testing of dermatophytes: Establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-344.
39. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2001; 39: 385-388.
40. Bozkurt M, Kustimur S, Gurer MA. Dermatofit suslarinin imidazol turevlerine karsi in vitro duyarliligi. Mikrobiol Bult 1989; 23: 64-70.
41. Goh CL, Tay YK, Ali KB et al. In vitro evaluation of griseofulvin, ketoconazole, and itraconazole against various dermatophytes in Singapore. Int J Dermatol 1994; 33: 733-737.
42. Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 117: 16-19.
43. Hart R, Bell-Syer SE, Crawford F et al. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ 1999; 319: 79-82.